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ARTICLE OPEN
High frequency of pathogenic germline variants within
homologous recombination repair in patients with advanced
cancer
Birgitte Bertelsen1, Ida Viller Tuxen2, Christina Westmose Yde1, Migle Gabrielaite 1, Mathias Husted Torp1, Savvas Kinalis1,
Olga Oestrup1, Kristoffer Rohrberg2, Iben Spangaard2, Eric Santoni-Rugiu3, Karin Wadt 4, Morten Mau-Sorensen2, Ulrik Lassen2 and
Finn Cilius Nielsen1
Genomic screening of cancer patients for predisposing variants is traditionally based on age at onset, family history and type of
cancer. Whereas the clinical guidelines have proven efficient in identifying families exhibiting classical attributes of hereditary
cancer, the frequency of patients with alternative presentations is unclear. We identified and characterized germline variants in 636
patients with advanced solid cancer using whole exome sequencing. Pathogenic and likely pathogenic germline variants among
168 genes associated with hereditary cancer were considered. These variants were identified in 17.8% of the patients and within a
wide range of cancer types. In particular, patients with mesothelioma, ovarian cancer, cervical cancer, urothelial cancer, and cancer
of unknown primary origin displayed high frequencies of pathogenic variants. Variants were predominantly found in DNA-repair
pathways and about half were within genes involved in homologous recombination repair. Twenty-two BRCA1 and BRCA2 germline
variants were identified in 12 different cancer types, of which 10 (45%) were not previously identified in these patients based on the
current clinical guidelines. Loss of heterozygosity and somatic second hits were identified in several of the affected genes,
supporting possible causality for cancer development. A potential treatment target based on the pathogenic germline variant could
be suggested in 25 patients (4%). The study demonstrates a high frequency of pathogenic germline variants in the homologous
recombination pathway in patients with advanced solid cancers. We infer that genetic screening in this group of patients may
reveal high-risk families and identify patients with potential PARP inhibitor sensitive tumors.
npj Genomic Medicine            (2019) 4:13 ; https://doi.org/10.1038/s41525-019-0087-6
INTRODUCTION
Precision medicine using next-generation sequencing (NGS) is
rapidly being implemented in clinical oncology aiming to identify
actionable tumor aberrations to guide trial allocation.1–5 Different
strategies based on tumor profiling are employed to select
patients for clinical trials but so far the significance of germline
findings is incompletely understood. The American College of
Medical Genetics and Genomics/Association for Molecular Pathol-
ogy (ACMG/AMP) are recommending return of germline findings
in 59 genes in clinical exome and genome sequencing, of which
29 are associated to hereditary cancer.6,7 However, there are still a
number of unresolved issues regarding handling of returns and
clinical implementation.
Depending on the patient cohort and the method used for
identification of germline variants previous studies have reported
a prevalence of putative pathogenic germline variants in
4.3–17.5% of cancer patients.8–11 In particular, pathogenic variants
in the two high penetrance genes BRCA1 and BRCA2, known to
predispose to breast and ovarian cancer, are frequently
observed.12 Thus, 72% of women carrying a BRCA1 mutation
and 69% with a BRCA2 mutation will develop breast cancer by the
age of 80, while up to 44% with a BRCA1 mutation and 17% with a
BRCA2 mutation will develop ovarian cancer.13 Mutations in BRCA1
and BRCA2 however also increase the risk of other cancers,
including pancreatic,14 fallopian tube, and peritoneal cancer.15,16
Men with BRCA2 mutations, and to a lesser extent BRCA1
mutations, are also at increased risk of breast17 and prostate
cancer.18,19 Several other genes have been linked to hereditary
cancer. The mismatch repair (MMR) genes MLH1, MSH2, MSH6, and
PMS2 are associated with hereditary nonpolyposis colorectal
cancer (HNPCC)20 and APC mutations are found in individuals
with familial adenomatous polyposis (FAP).21 Mutations in TP53,
PTEN, CDH1, CHEK2, ATM, RAD51D, PALB2, and FANCM have been
associated with increased risk of breast cancer22,23 or prostate
cancer,19 although with varying penetrance. In particular loss-of-
function germline variants in PALB2 increase the risk of breast
cancer before 40 years of age eight times24 and heterozygous
mutations within the FANCM gene were recently demonstrated to
be associated with familial breast cancer, in particular for early-
onset or triple-negative breast cancer.23 Furthermore, bi-allelic
inherited germline variants in ataxia telangiectasia mutated (ATM)
result in the multisystem disorder ataxia telangiectasia syndrome,
which manifests with progressive neurological disease and an
increased predisposition to lymphoid, gastric, breast, central
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nervous system, and skin cancer, as well as other cancers.25,26
Studies have shown a moderate increased risk of breast cancer in
heterozygote carriers of pathogenic ATM variants.27 Studies on
germline ataxia-telangiectasia and Rad3-related (ATR) mutations
with respect to cancer susceptibility have mainly been incon-
sistent or inconclusive.28 Thus, the role of ATR variants for cancer
susceptibility remains unclear.
Most of the known cancer susceptibility genes are involved in
maintenance of genomic integrity, safeguarding DNA from
mutations that ultimately could lead to malignancy. BRCA1 and
BRCA2 proteins are key players in the molecular events following
double-stranded DNA damage and homologous recombination
(HR),29 while ATM, ATR, CHK1, CHK2, and Tumor suppressor p53
proteins are all central players in sensing and orchestrating the
checkpoint signaling from double strand breaks (DSBs) to DNA
repair.30 In contrary, the MMR system recognizes and repairs DNA
errors from mismatched nucleotides with MSH proteins being key
players in recognizing and initiating the MMR repair process.31
The response to various therapies are affected by the hereditary
predispositions. In case of BRCA1 or BRCA2, mutations improve
responsiveness to platinum-based chemotherapy, as well as poly
(ADP-ribose) polymerase inhibitor (PARPi) treatment.32 In parti-
cular, PARPi treatment of patients with ovarian and breast cancer
carrying germline BRCA1/2 mutations has shown an exceptional
increase in response rate and progression-free survival, illustrating
the first clinical proof for the concept of synthetic lethality.33 These
results have led to clinical approval of PARPi in ovarian cancer, and
in January 2018, also for the treatment of germline BRCA1/2
mutated metastatic breast cancers, thereby becoming the first
targeted therapy for patients with breast cancer carrying BRCA1/2
mutations.34 In addition, prostate cancers with somatic or germ-
line variants in DNA-repair genes including BRCA2 and ATM
displayed a high response rate to PARPi treatment.35 Finally,
mutations in MMR genes are associated with microsatellite
instability and high mutational burden which confer a better
response to anti-PD-1 immunotherapy.36,37
In this study we examined the clinical significance of germline
screening in patients with advanced cancer. We investigated a
cohort of 636 advanced cancer patients for pathogenic germline
variants to gain insights into possible new associations between
germline variants, cancer types and molecular pathways.
RESULTS
Germline variants: frequency and characteristics
A total of 636 patients with advanced cancer referred to the Phase
1 unit were included in the study. The patient characteristics are
summarized in Table 1. Out of these patients, 17.8% (n= 113)
were shown to have a pathogenic or likely pathogenic (hereafter
collectively referred to as pathogenic) germline variant in at least
one of the 168 cancer-associated genes tested (Supplementary
Table 1; excluding heterozygous variants in genes known to have
a recessive inheritance pattern) (Table 1). Four patients carried two
pathogenic variants while two patients carried three pathogenic
variants (Supplementary Table 2). In addition, 16 patients were
heterozygous for pathogenic variants in genes known to have a
recessive pattern of inheritance, i.e., the colorectal cancer (CRC)
predisposition genes MUTYH and NTHL1 (Supplementary Table 3).
As we did not identify any patients with homozygous variants nor
potentially compound heterozygous variants, all presumed genes
associated with recessive conditions were excluded from further
analysis.
In total, 121 germline variants classified as pathogenic (n= 110)
or likely pathogenic (n= 11) were identified in only 42 out of the
168 investigated genes (25%). Variants consisted of 51 frameshift
variants (42%), 42 nonsense variants (35%), 18 splice-site variants
(15%), 9 missense variants (7%) and one start loss variant (1%)
(Fig. 1b, Supplementary Table 4). A small number of genes were
overrepresented with respect to germline mutational burden.
Fifteen pathogenic variants were identified in BRCA2 and CHEK2,
while seven pathogenic variants were identified in BRCA1, thus,
about one third of the pathogenic variants were identified in these
three genes (Fig. 1c, Supplementary S4). The CHEK2 variant
c.1100del, p.Thr367Metfs*15, which has an allele frequency of
0.2% in non-Finish Europeans (GnomAD) and is known to have
reduced penetrance38 was e.g., observed in 12 patients (1.9%).
Most variants were however only represented 1–3 times, thus
excluding any founder effect on the results. Aside from the 10
genes that were most frequently found to have germline
Table 1. Patient characteristics
Total (n= 636) Patients with
pathogenic variant
(n= 113)
Gender
Female 321 (50%) 58 (51%)
Male 315 (50%) 53 (49%)
Age at diagnosis
Median, range 57 (16–82) 54 (26–77)
History of prior cancera 103 (16%) 24 (22%)
Tumor type
Colorectal cancer 141 (22%) 27 (24%)
Breast cancer 85 (13%) 16 (14%)
Bile duct cancer 47 (7%) 8 (7%)
Pancreatic cancer 43 (7%) 7 (6%)
NSCLC 33 (5%) 4 (4%)
Prostate cancer 26 (4%) 3 (3%)
Ovarian cancer 23 (4%) 7 (5%)
Urothelial cancer 20 (3%) 5 (4%)
Gastric cancer 20 (3%) 1 (1%)
Cervical cancer 18 (3%) 1 (1%)
Others 17 (3%) 1 (1%)
Cancer of unknown primary
origin (CUP)
16 (3%) 4 (4%)
Sarcoma 14 (2%) 3 (3%)
Head and neck cancer 14 (2%) 2 (2%)
Neuroendocrine cancer 13 (2%) 1 (1%)
Malignant Mesothelioma 12 (2%) 7 (6%)
Melanoma 12 (2%) 2 (2%)
Esophageal cancer 11 (2%) 2 (2%)
SCLC 11 (2%) 0
Hepatocellular cancer 10 (2%) 2 (2%)
Adrenocortical cancer 8 (1%) 0
Endometrial cancer 8 (1%) 1 (1%)
Thymoma 8 (1%) 1 (1%)
Renal cell carcinoma 6 (1%) 2 (2%)
Adenoid cystic carcinoma
(salivary gland)
5 (1%) 1 (1%)
Myoepithelial carcinoma 4 (0.5%) 0
Glioblastoma 4 (0.5%) 0
Anogenital cancer 3 (0.5%) 0
Germ cell cancer 2 (0.5%) 0
Vulvovaginal cancer 2 (0.5%) 1 (1%)
aBasal cell carcinoma is not included
B. Bertelsen et al.
2
npj Genomic Medicine (2019)    13 Published in partnership with CEGMR, King Abdulaziz University
1
2
3
4
5
6
7
8
9
0
()
:,;
pathogenic variants, no genes were found to have such variants in
more than three individuals (Fig. 1c, Supplementary Table 4).
Pathogenic variants were associated with every tumor type
found in at least 10 individuals, except in the case of patients
suffering from small cell lung cancer (SCLC) (Fig. 1d). However, the
variant frequency varied greatly over the different tumor types.
The incidence of patients with germline pathogenic variants
ranged from 58% in malignant mesothelioma, 30% in ovarian
cancer, 28% in cervical cancer, 25% in cancer of unknown primary
origin and 25% in urothelial cancer, and down to 5% in gastric
cancer (Fig. 1d).
Pathogenic variants affecting HR
Genes encoding proteins within the HR pathways, including
BRCA1, BRCA2, and genes in the Fanconi anemia pathway,
generally harbored more pathogenic germline variants (52%)
than genes within other pathways such as DNA damage
checkpoint control (22%), nucleotide excision repair (7%), MMR
(3%) and other pathways (16%) (Fig. 2a). However, looking into the
different tumor types, particularly pancreatic cancer, mesothe-
lioma and ovarian cancer show a tendency for enrichment of
pathogenic variants in genes within the HR pathway with 70–85%
of the identified variants located within these genes; although the
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Fig. 1 Identification and classification of pathogenic germline variants. a Schematic outline of the strategy for identification of pathogenic
germline variants in the cohort. In total, whole-exome sequencing (WES) data from 636 patients were used for variant calling with GATK
bioinformatic pipeline, followed by filtering using a prespecified gene list (Supplementary Table 1). Variant analysis and classification was done
as described in the Methods section. b Distribution of mutational type among the 121 identified pathogenic and likely pathogenic mutations
was calculated. c The most commonly mutated genes (>three pathogenic or likely pathogenic variants) are shown, ranked from bottom to top
with CHEK2 and BRCA2 being the most frequently mutated of the genes included in this study (both n= 15). Distribution of mutational type is
included in the figure. d The fraction of pathogenic or likely pathogenic variant was calculated for each cancer type and the graph shows the
ranking of cancer types with highest fraction of germline variant. Only cancer types represented by >10 patients are included in the Figure.
The bracket after each cancer type indicates the number of patients with germline variant/total number of patients for each cancer type
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number of included patients within these cancer types is limited
(Fig. 2b). Interestingly, more than half of the possible pathogenic
variants identified in patients with mesothelioma were located
within genes of the Fanconi anemia pathway (FANCA, FANCC,
FANCD2, and FANCM). Furthermore, remarkably, only a single
pathogenic variant (MLH1 p.Pro648Ser) within the MMR genes was
identified in patients with CRC (Fig. 2b, Supplementary Table 4).
Loss of Heterozygosity (LOH) and second hit
To further elucidate the causative role of the identified pathogenic
germline variants, the individual tumor samples were assessed for
the allele frequency of the identified germline variants, as loss of
heterozygosity (LOH), thus, loss of the wild-type allele, can indicate
causality. However, it is important to state that LOH can also occur
by chance as the consequence of another pathogenic variant, and
Colorectal cancer (n=30)
All cancer types (n=121)
Breast cancer (n=16) Pancrea c cancer (n=9)
Mesothelioma (n=7) Ovarian cancer (n=7) Cervical cancer (n=5)
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ERCC2
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Fig. 2 Germline variants are predominantly found in genes involved in DNA checkpoint and repair pathways. a Distribution of molecular
pathways among the 121 identified pathogenic or likely pathogenic variants. b For each of the selected cancer types; colorectal cancer, breast
cancer, pancreatic cancer, mesothelioma, ovarian cancer, and cervical cancer, the distribution of molecular pathways are shown. The mutated
genes are indicated in the figure. Full information about each variant is found in Supplementary Table 4. The number of patients for each
cancer type is shown in bracket
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that causality of a pathogenic variant cannot be excluded solely
based on missing LOH and vice versa. The allele frequency of all
identified germline variants in blood samples was <65%,
indicating that only heterozygous variants were identified
(Fig. 3a). When analyzing each of the pathogenic germline
variants in the tumor sample from the same patient, allele
frequencies above 65% were observed, indicating LOH of these
genomic regions. Due to the fact, that the tumor biopsies
contained varying amounts of normal tissue, LOH may be under
estimated using this approach. Furthermore, tumor heterogeneity
may mask LOH in a subpopulation of cancer cells. On the contrary,
chromosomal instability may give rise to LOH of genes that are
not causal for the cancer, showing the results should be
interpreted with caution. Using the cut-off value of 65% allele
frequency, 19% of the overall identified pathogenic germline
variants showed LOH in tumor samples (Fig. 3b), while 27% of the
identified germline variants known to play a role in HR showed
LOH in tumor samples (Fig. 3c), thus, supporting the importance of
HR in the development of cancer in this patient cohort. The tumor
allele frequency of all identified pathogenic germline variants are
indicated in Supplementary Table 4. Focusing on the germline
variants identified within genes involved in HR, most variants
showing LOH were in agreement with known
genotype–phenotype correlation as indicted by the observation
of BRCA1/2 variants in breast, ovarian and prostate tumor samples
and BAP1 variants in uveal melanoma (Fig. 3d). However, also less
well-established correlations were identified. For example, a
BRCA2 nonsense variant (p.Lys944Ter)39 and a FANCM nonsense
variant (p.Arg486Ter)40 displayed LOH in the tumor samples of
two patient with CRC, as well as LOH of a NBN missense variant (p.
Ile171Val) in the tumor sample of a patient with NSCLC previously
suggested to increase the risk of developing NSCLC.41 In addition,
a WRN nonsense variant (p.Arg369Ter) showed a high allele
frequency (>85%) in the tumor sample of a patient with pancreatic
cancer in line with previous suggestions that loss-of-function
variants within WRN might be associated with an increased
predisposition to pancreatic cancer.42 Of note, the LOH in tumor
tissue detected by NGS was confirmed by SNParray.
Another indication of causality of germline variants is, according
to Knudson’s two-hit hypothesis,43 the identification of a second
hit in the tumor sample within the same gene as the identified
germline variant but on the opposite allele. In total, we identified a
pathogenic second hit in six patients (Fig. 3e). Some of these
findings, such as second hits in ATM and BLM in CRC patients, were
supportive of previously suggested cancer associations.44,45 A
second hit in BRCA2 was also observed in a patient with ovarian
cancer, however, further analysis revealed that the germline
variant, c.7069_7070del, p.Leu2357Valfs*2, and the somatic
variant, c.7065del, p.Glu2355Aspfs*12, were located on the same
allele, thus, the somatic variant would be expected to restore the
interrupted reading frame (resulting in p.Glu2355_Phe2356delin-
sAsp) reversing the pathogenicity of the germline variant. This
paradoxical phenomenon of a restoring mechanism has pre-
viously been described for BRCA variants in platinum resistant
ovarian cancer.46,47
We also identified previous unknown associations such as a
second hit in ATM of a patient with bile duct cancer and a second
hit in BLM in a patient with thymoma. Furthermore, a patient with
urothelial cancer and a pathogenic germline variant in BRCA2 was
found to have two second hits. The two somatic variants, c.517-
1G>A and c.631+3A>G, were located on opposite alleles,
however, it was not possible to determine the allelic location of
the germline variants in the other cases (Fig. 3e).
Co-occurrence of germline and somatic variants in the HR
pathway
Furthermore, we examined the occurrence of somatic pathogenic
variants in genes associated with HR repair and DSB repair and
characterized the gene expression profiles of 534 tumors from the
patients. Ninety-two of the tumors were from patients with
germline variants. In total, 57 tumors exhibited mutations in the
HR pathway and more than half of these mutations were found in
BAP1 and BRCA2. Seven of the mutations occurred in tumors from
patients carrying pathogenic germline variants. Employing pre-
viously established gene expression signatures for HR deficiency
(HRD) and PARPi sensitivity,48 we noticed that tumors from
patients with advanced cancer exhibit a higher degree of HRD
than primary cancers (Fig. 4a). Normal tissues do not exhibit HRD
with the exception of testis, which was included as control. 79%
(15 out of 19) of the tumors with LOH or a concurrent somatic
mutation were predicted to have HRD and 37% (7) of these were
predicted to be PARPi sensitive (Fig. 4b). Taken together, we infer
that co-occurrence of germline and somatic variants in the HR
pathway may play a role in cancer development and treatment
response.
BRCA in atypical cancer types and less established associations in
breast cancer
Overall, pathogenic BRCA1 and BRCA2 germline variants were
observed in patients with expected malignancies such as breast,
ovarian, prostate and pancreatic cancer, a large proportion of which
showed loss of the wild-type allele in the tumor sample (Fig. 3d).
BRCA1/2 germline variants were also observed in patients with other
more atypical cancer types such as salivary adenoid cystic
carcinoma, bile duct cancer, endometrial cancer, mesothelioma,
esophageal cancer and urothelial cancer, however, without a clear
loss of the wild-type allele in the tumor sample (Supplementary
Table 4). Pathogenic BRCA1 and BRCA2 variants were identified in
7% of the investigated patients with breast cancer. In addition, this
patient group harbored pathogenic germline variants in other genes
previously known or suggested to be associated with breast cancer
to a varying extent, including ATR, CDH1, CHEK1, CHEK2, ERCC2,
FAN1, SEC23B, and SMAD9. However, with the exception of a single
patient carrying the moderately penetrant CHEK2 variant, c.1100del,
p.Thr367Metfs*15, none of these variants had indications of LOH in
the breast tumor samples.
Categorization of variants in respect to clinical significance
To further evaluate whether variants played a role in the cancer
etiology of each case, all pathogenic variants were categorized
into three groups based on their clinical significance and thus
potential causality (Supplementary Table 4). Group 1 includes
likely causal variants, representing genes known to be associated
with an increased risk of the given cancer type, e.g. BRCA1 and
BRCA2 in breast, ovarian and pancreatic cancer, BAP1 in
melanoma and mesothelioma, etc. This group also includes
variants with a reduced penetrance, e.g., the CHEK2 c.1100del
variant in breast cancer. About one fourth of the variants falls into
this category and are thus likely to be causative and a primary
diagnostic finding relevant to the cancer type. Group 2,
constituting about 20% of the variants, represents interesting
findings that show new possible associations between a gene
and a given cancer type but with limited or no previously known
predisposition. This group also includes variants with a high
tumor allele frequency or genes/gene-families overrepresented in
a given cancer type in our data set, e.g. genes in the Fanconi
anemia pathway observed in mesothelioma. Group 3, represent-
ing about half of the cases, includes genes known to be
associated to a cancer predisposition syndrome but unlikely to
B. Bertelsen et al.
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be causative for the observed phenotype, e.g. based on lacking
expression of the variant in the tumor sample, or where lack of
evidence from the literature in a given cancer type makes the
causality inconclusive.
It should be noted, however, that these categorizations are
merely an assumption of causality. A strong family history and
clear co-segregation data would provide further evidence for
causality. However, due to ethical considerations and the scope of
a b
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 15 30 45 60 75 90
)xa
m fo 
%( ycneu qerF
Variant allele frequency (%)
Germline variants
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 15 30 45 60 75 90
Fr
eq
ue
nc
y 
(%
 o
f m
ax
)
Variant allele frequency (%)
Tumor variants
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 15 30 45 60 75 90
Fr
eq
ue
nc
y 
(%
 o
f m
ax
)
Variant allele frequency (%)
Homologous recombinaonc
d Cancer type Gene Germline variant Tumor AF 
(%)
Age at 
diagnosis
Prior cancer Family cancer 
history1
Known germline
variant
Breast cancer BRCA1 c.2475del, p.Asp825Glufs*21 74.7 33 No No Yes
Breast cancer BRCA1 c.1823_1826del, p.Lys608Ilefs*3 69.7 32 No Yes Yes
Ovarian cancer BRCA1 c.4301del, p.Ser1434Mes*22 74.1 52 No - Yes
Breast cancer BRCA2 c.9016_9017del, p.Tyr3006Glnfs*11 91.0 33 Yes2 Yes Yes
Breast cancer BRCA2 c.2808_2811del, p.Ala938Profs*21 78.6 48 No Yes Yes
Breast cancer BRCA2 c.6373del, p.Thr2125Profs*12 70.2 35 Yes2 Yes Yes
Prostate cancer BRCA2 c.6373del, p.Thr2125Profs*12 84.0 53 Yes2 - No
Colorectal cancer BRCA2 c.2830A>T, p.Lys944Ter 67.5 64 Yes2 - No
Melanoma BAP1 c.1254T>A, p.Tyr418Ter 87.1 39 No No No
CUP FANCC c.67del, p.Asp23Ilefs*23 73.6 75 No No No
Colorectal cancer FANCM c.1456C>T, p.Arg486Ter 90.9 70 No No No
Cervical cancer NBN c.432del, p.Glu145Lysfs*11 82.1 32 No No No
NSCLC NBN c.511A>G, p.Ile171Val 67.4 77 Yes3 No No
Pancreac cancer WRN c.1105C>T, p.Arg369Ter 85.1 68 No No No
e
BRCA2
BLM
Urothelial cancer 
Colorectal cancer
ATM
Bile duct cancer 
BRCA2
BLM
Ovarian cancer 
Thymoma
ATM
Colorectal cancer
19% 27%
Fig. 3 Analysis of loss-of-heterozygosity (LOH) and second hits from whole-exome-sequencing data from paired tumor samples. a The
histogram shows variant allele frequency distribution of all germline variants (n= 121), demonstrating that most variants are called close to
50% as expected for heterozygous variants. b Histogram of tumor allele frequencies of all variants shown in a. c The histogram shows tumor
allele frequencies of the variants in homologous recombination genes. Variants with tumor allele frequency > 65% are indicated in red. d An
overview of patients with variants in homologous recombination pathway genes with allele frequency > 65%. e Potential second hits are
shown; germline variants are indicated in blue, while somatic variants are shown in red. 1Known cancer in first or second degree relatives,
2Breast cancer, 3Melanoma
B. Bertelsen et al.
6
npj Genomic Medicine (2019)    13 Published in partnership with CEGMR, King Abdulaziz University
this study it was not possible to obtain pedigrees or blood
samples of relatives in each investigated family.
Clinical implications for detection of pathogenic germline variants
Of the 113 patients carrying a pathogenic germline variant, the
genetic findings were suggested to have a potential important
implication to 36 of the patients and/or their families with respect
to either treatment, prophylactic surgery, inclusion in screening
programs or genetic counseling (Fig. 5; Supplementary Table 5).
Since this study was done retrospectively, the majority of the
patients were deceased and, in these cases, return of the results
had no clinical relevance, neither in respect to treatment of the
patients nor from a diagnostic point of view. Due to ethical
considerations, we have chosen to follow the ACMG/AMP
recommendations, in combination with recent evidence and the
individual family history. In total, 26 variants were recommended
returned to the patients or their families. Half of these patients
had no previous implications of hereditary cancer predisposition
and variants had not previously been identified in their families.
Potential actionable treatment targets were identified in 25
patients (4%) and included PARPi for patients with a pathogenic
BRCA1/2 variant (n= 21) and immunotherapy for patients harbor-
ing a pathogenic variant within the MMR genes (n= 4).
DISCUSSION
Predisposing germline variants has long been recognized for
specific cancer types, such as breast, ovarian and CRC. Genomic
screening is mainly based on the age at onset and family history,
whereas it is unclear if predisposing germline variants are
overlooked in other patient populations. Current results from
germline studies of The Cancer Genome Atlas49 or datasets
derived from routine clinical tumor sequencing for allocation of
cancer patients to early clinical trials8–11 have indicated that
variants in cancer susceptibility genes may be more frequent in
atypical cancer forms than anticipated.
We analyzed the presence of germline variants in consecutive
patients with advanced cancer from the CoPPO study that
comprise patients with exhausted treatment options and
observed a prevalence of pathogenic germline variants in ~18%
among the patients.
As mentioned, studies have reported pathogenic germline
variants in various cancer populations.8–11,49 Our data are
remarkably similar to the recent results from Mandelker et al.
that discovered pathogenic variants in 19.7% of advanced cancer
patients.8 While we employed a gene list of 168 genes previously
associated with cancer, Mandelker et al. employed a gene panel of
76 genes, all of which were included in our study, except for five
genes where no pathogenic variants were identified. Pathogenic
variants were identified in only 25% of the 168 genes investigated
in our study, indicating that germline testing may be feasible with
a relatively narrow list of genes. Generally, there is a high
consistency in the frequency of pathogenic variants in the
overlapping genes; although Mandelker et al. reports a larger
number of variants within APC and the MMR genes. Of notice, the
gene panel employed by Mandelker et al. did not include any of
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Fig. 4 Homologous recombination defects in tumors from patients with advanced cancer. Panel a shows a comparison of the percentage of
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the genes in the Fanconi anemia pathway, where we observed a
relatively large proportion of pathogenic variants, while our study
did not include heterozygous variants in MUTYH in the overall
frequency of identified germline variants in contrast to Mandelker
et al. Our cohort shares similarities with the study from Mandelker
et al. comprising advanced cancer patients and being rich in
breast and CRC. In contrast, cohorts from other studies vary both
in the number of cancer types and the composition of advanced
versus primary cancers.45,50–53
Mesothelioma exhibited the highest frequency of pathogenic
germline variants with seven out of twelve patients (58%) being
carriers. Germline variants in mesothelioma have previously been
reported with a frequency of 10–12% in patients.49,51 In
concordance with previous studies, the majority of the mutated
genes were involved in HR (BAP1, BRCA2, FANCA, FANCC, FANCD2,
and FANCM) and a single gene was involved in nucleotide excision
repair (XPC). BAP1 is the best studied predisposition gene for
mesothelioma, supported by both clinical findings and mouse
models.54 However, our results may suggest a more heteroge-
neous genetic background for the disorder, dominated by genes
involved in HR. Three of the mesothelioma patients carrying a
pathogenic germline variant (in FANCD2, FANCM, and XPC) had
first-degree relatives with mesothelioma and a known history of
asbestos exposure, implying a gene-environment interaction,
where the genetic background increases the sensitivity of the
patient to the carcinogenic effect of asbestos.55 The high
frequency of pathogenic germline variants in mesothelioma
indicates that this group of patients should be offered mutation
screening on a routine basis—especially if they have a family
history of mesothelioma or other cancer types associated with
mutations in HR genes. Furthermore, in the light of the promising
effects of PARPi therapy in treatment of BRCA positive ovarian and
breast cancer patients, clinical trials on PARPi treatment in patients
with mesothelioma could be warranted.
CRC was the predominant cancer type and 19% of the patients
exhibited a pathogenic germline variant. Among these only a
single variant was found in one of the four MMR genes that
predispose to HNPCC.53,56 Neither did we identify pathogenic
variants in the APC gene that predispose to FAP, nor did we
observe homozygous or compound heterozygous germline
variants in the recessive CRC predisposition genes MUTYH and
NTHL1. This may be related to the fact that most Danish HNPCC
and polyposis families are under surveillance by the national
registry as Denmark has had a long tradition for registration and
screening of HNPCC families. Consequently, the majority of
HNPCC families are now included in the relevant screening
programs and subject to preventive treatment. Therefore, few
patients are expected to develop advanced cancer due to the
successful preventive program. Obviously, patients with de novo
MMR mutations could be represented in our study, but a number
of studies have indicated that Lynch de novo mutation are
relatively rare compared to e.g., APC related polyposis and it is
estimated that only 1–3% of all HNPCC cases are caused by MMR
de novo mutations.57
Due to the clinical setting of the CoPPO trial, cancers in our
study, in general, represent a heavily pretreated, drug-resistant
phenotype with a median of three prior standard treatment
regimens (range 1–12).5 We speculate that the selection of
patients in our cohort with advanced cancer displaying a drug-
resistant phenotype might be enriched for either germline or
somatic variants within specific pathways such as the HR pathway.
Paradoxically, HRD is known to predict good response to
platinum-based chemotherapy,32 however, the majority of
patients in our cohort have already previously been treated with
chemotherapy such as cisplatin, carboplatin or oxaliplatin, either
alone or in combination with other chemotherapy. Therefore,
even though we report findings of previously undiscovered
pathogenic germline variants, particularly in BRCA1 and BRCA2,
the potential clinical benefit of PARPi treatment in these drug-
resistant patients at advanced stage of cancer remains unclear.
The occurrence of pathogenic germline variants in patients with
advanced cancer raises the question of whether genetic testing
should become part of the clinical routine for a group of patients.
In this context it is important to distinguish between pathogenic
variations in the well-established actionable genes such as BRCA1
and BRCA2 and novel candidate genes such as FANCM and BLM. Of
note, we could classify about haft of the variants as having either
likely or possible clinical significance for the cancer; however, with
the caution that further validation is needed to confirm these
potential causalities, including pedigree of affected families and
functional studies of variants. Counseling is generally based on
solid cohort and co-segregation data, but these may not be
available for variants in the emerging group of cancer suscept-
ibility genes. Obviously, we could decide to selectively screen a
small panel of actionable cancer genes, but we risk that patients or
healthy carriers exhibiting pathogenic variants in emerging factors
may wrongly be excluded from targeted treatment or pre-
symptomatic screening programs. Another direction is to employ
structural and functional analysis for variant classification. In this
context recent procedures to establish defects in HR from
mutation patterns may pave the way for including emerging
genes and variants in genetic testing and counseling.58,59
Evidently, unfounded classification of genetic variants is harmful
to the patient and great care should be taken to generate
Fig. 5 Flowchart highlighting the clinical utility of germline testing
in our cohort. Pathogenic germline variants were found in 113
patients. A relevant treatment could have been recommended in 25
patients based on the identified variant. Thirty-six variants were
selected for further evaluation due to potential clinical implication
for the patients or their families (Supplementary Table 5). In 26
cases, return was recommended based on ACMG/AMP recommen-
dations, recent evidence and the individual family history. Of these,
13 variants were previously identified. 1No return was recom-
mended for the BRCA1 variant p.Arg1699Gln, since it is a moderate
risk variant. Genes shown in red indicate inclusion in ACMG/AMP
recommendations for return of results
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common protocols and collaborative efforts to meet the required
standards.
In conclusion, our study of patients with advanced solid cancers
showed a high frequency of germline variants, especially in the HR
pathway. This implies that testing for selected germline variants in
precision oncology may contribute to the improved treatment of
cancer patients.
METHODS
Patients
This study included a cohort of patients enrolled in the Copenhagen
Prospective Personalized Oncology (CoPPO) study (NCT02290522) from
May 2013–February 2018.5,60 The CoPPO study aims to investigate the
clinical utility of using molecular profiling to select patients for phase 1
trials. Patients with exhausted treatment options considered eligible for
phase 1 trials were offered enrolment. All patients fulfilled the inclusion
criteria including: life expectancy ≥ 3 months, normal organ function,
age ≥ 18 years, Eastern Cooperative Oncology Group (ECOG) performance
status 0 or 1, and lesions assessable for biopsy. Basic characteristics and
clinical information were collected at baseline in a prospectively collected
database. Regulatory approvals from the Regional Ethics Committee and
the Danish Data Protection Agency were obtained (Danish Ethical
Committee, file number: 1300530). All patients provided signed informed
written consent.
Whole exome sequencing
Whole exome sequencing (WES) was performed as previously described.5
In brief, DNA was extracted from whole blood samples and matched tumor
biopsies. Sequencing libraries were prepared from 200 ng of DNA.
Fragmentation was done on Covaris S2 (Agilent) to ~300 base pair
fragments and adaptor ligation was performed using KAPA HTP Library
Preparation Kit. Exomes were enriched with SureSelectXT Clinical Research
Exome kit (Agilent). Paired-end sequencing was performed, aiming at an
average coverage of 50–100×, using the HiSeq2500 or NextSeq500
platforms from Illumina.
Sequencing data pre-processing
Sequenced reads were trimmed and mapped to hg19/GRCh37 reference
genome using BWA-MEM v0.7.12 software.61 Alignment quality control
was performed with mosdepth v0.2.062 for all the exons of the genes of
interest (Supplementary Table 1). Alignment files were pre-processed with
GATK v3.8.0 suite63 using Best Practices guidelines. For germline variant
calling alignment files were analyzed with GATK v3.8.0 suite’s Haplotype-
Caller64 using Best Practices guidelines for germline variant calling. Variant
files were filtered so all the variants: (1) were covered by at least 10 reads,
(2) had variant score higher or equal to 20, (3) were within the genes of
interest using a list of 168 cancer-associated genes (Supplementary Table
1). The list was based on cancer-related genes from the ACMG/AMP’s
recommendations, high penetrance cancer-related genes, and review of
the literature for additional cancer-related genes with modes of
inheritance.6,7,10,11 Somatic variant calling in tumor samples was performed
by MuTect239 from GATK v3.8.0 suite.
Variant analysis
Called germline variants were filtered using Ingenuity Variant Analysis (IVA;
http://ingenuity.com). First, variants with call quality < 20 and read depth <
10; were disregarded. Second, variants with an allele frequency > 1% of the
public variant database including 1000 genomes project (http://
www.1000genomes.org), ExAC (http://exac.broadinstitute.org), GnomAD
(http://gnomad.broadinstitute.org) or NHLBI ESP exomes (http://evs.gs.
washington.edu/EVS/), or unless established as a pathogenic common
variant, were excluded. Third, only coding non-synonymous variants and
splice-site variants (+/−2bp) were kept. Finally, only variants with an allele
frequency > 20% were kept for further analysis.
Variant classification
All variants identified after IVA processing were divided into subgroups
based on the classification provided by IVA. All pathogenic or likely
pathogenic variants were manually classified following ACMG/AMP’s
recommendations,40 thus, using information about population allele
frequency, in silico tools including MaxEntScan65 for splice-site variants
and Align-GVGD66 for missense variants, literature search and in-house
databases. Furthermore, variants within BRCA1 and BRCA2 and within the
MMR genes (MLH1, MSH2, MSH6, and PMS2) classified as uncertain by IVA
were manually classified using the same procedure as well as the
guidelines provided by ENIGMA and InSiGHT, respectively. Finally, all
frameshift and nonsense variants classified as uncertain were manually
curated following the same procedure. All variants classified as pathogenic
(Class 5) or likely pathogenic (Class 4) after manual curation were
considered for further analysis, while variants classified as of unknown
significance (Class 3), likely benign (Class 2) or benign (Class 1) were
disregarded.
Transcriptome based analysis of HRD and sensitivity to cisplatin
and PARP inhibitors
Signatures of HR repair and DSB repair were examined in a set of primary
tumors67 and in 534 tumors from the patients in this study; 92 of these
tumors were from patients with pathogenic germline variants. Briefly, total
RNA was isolated and processed as described68 before samples were
labeled according to the manufacturer’s guidelines (Affymetrix, Santa
Clara, CA, USA). The labeled cRNAs were hybridized to the HG-U133plus2
GeneChip array, which query close to 48,000 genes by ∼56,000 probe sets.
After scanning, the data were RMA normalized and imported in Qlucore
Omics Explorer for further analysis. The classification was based on gene
expression signatures for HR deficiency, cisplatin and PARPi sensitivity
derived from McGrail et al.48 These signatures were originally generated
from expression data of 857 solid tumor cell lines from the Cancer Cell Line
Encyclopedia (CCLE) matched with drug sensitivity data from the
Genomics of Drug Sensitivity in Cancer (GDSC). Gene lists of each
signature were initially employed to provide a two-way hierarchical cluster
of the advanced cancer samples before two groups of characteristic
samples were used to build a second K-means based classifier that could
be employed in Qlucore Omics Explorer.
Ethical considerations regarding return of results
At study enrollment, patients received information about potential
germline findings and a written consent with degree of return of germline
findings was signed. The consent included a remark stating the obligation
to contact the patient or family members with important information
concerning specific germline findings. Regarding results from this retro-
spective study, all pathogenic germline variants with potential clinical
implications were evaluated and return of results was recommended
based on ACMG/AMP’s recommendations,6,7 recent evidence and the
individual family history. For all variants subjected to return, genetic
counselling of the patient and validation of results using an independent
blood sample were recommended. Furthermore, these variants will be
submitted to ClinVar.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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